Jacinto De La Cruz, San Jose State University
Inositol phosphate glycans (IPGs) are naturally occurring oligosaccharides that elicit insulin-like biological activity. Type II diabetes mellitus is a disorder in which cells do not properly respond to the presence of insulin, a phenomenon known as insulin resistance. In an earlier study, a synthetic IPG, pseudotetrasaccharide 4α, was synthesized and was reported to possess high insulin-like activity in rat adipocytes. However, a subsequent study reported that 4α was not highly insulin mimetic. Our current work is aimed at resynthesizing 4α, with the goal of unequivocally evaluating its biological activity. IPG 4α is being synthesized using the techniques of carbohydrate chemistry from mannose, glucosamine, and xylose precursors. Insulin mimetic glycans have the potential to become pharmaceuticals to benefit patients who suffered from type II diabetes.
Clinical Labeling of Medicinal Products: EU Clinical Trial Regulation
Tuesday, 03 May 2016 18.05
Design Considerations for WFI Distillation Systems Part 2
Thursday, 28 Apr 2016 18.04
2016 Annual Meeting Honorary Chair, Joseph Jimenez, Novartis
Tuesday, 26 Apr 2016 12.04